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Background: DLBS1442, a proprietary and standardized semipolar bioactive extract of the 
fruit Phaleria macrocarpa, is preclinically proven to have anti-inflammatory properties. The 
current clinical study evaluated the efficacy and safety of DLBS1442 in alleviating symptoms 
of premenstrual syndrome and primary dysmenorrhea.
Methods: This was an open study over four menstrual cycles (with two control cycles, followed 
by two treatment cycles). Women with premenstrual syndrome and/or primary dysmenorrhea, 
18–40 years of age, and with a regular menstrual cycle were included in the study. In the treat-
ment cycles, DLBS1442 extract was given as a 100 mg capsule two or three times daily (for 
those with mild and moderate-to-severe baseline abdominal pain, respectively), for an average 
of six days, ie, three days before until the end of the first three days of the menstrual period. 
Throughout all four study cycles, daily self-assessment of symptoms related to premenstrual 
syndrome was made by each subject using a visual analog scale (VAS). Data were descriptively 
analyzed and profiled in curves of VAS score versus time point evaluation starting from day 5 
before menstruation to day 5 of menstruation.
Results: Twenty-three subjects of mean age 27.35 ± 5.73 years were evaluable for the intention 
to treat analysis. Most subjects experienced the primary efficacy variable (abdominal pain), 
peaking on days 1–2 of the menstrual phase, with a mean VAS score of 36.8 ± 24.3 mm and 
30.0 ± 29.6 mm, respectively, during control cycles. DLBS1442 markedly reduced VAS scores 
by 13.76 ± 28.27 mm (37.46%) and 13.28 ± 29.06 mm (44.28%), respectively. Other symptoms 
of premenstrual syndrome were also markedly alleviated by DLBS1442. Some mild adverse 
events were observed and resolved by the end of the study.
Conclusion: This preliminary study indicates the effectiveness of DLBS1442 in alleviating 
primary dysmenorrhea and abdominal pain, as well as other symptoms related to premenstrual 
syndrome. DLBS1442 was safe and well tolerated in women with premenstrual syndrome 
and/or dysmenorrhea.
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Introduction
Premenstrual syndrome and dysmenorrhea affect a large proportion of women of 
child-bearing age. Premenstrual syndrome is characterized by consistent recurrence 
of emotional and physical symptoms during the luteal phase of the menstrual cycle. 
It has been reported that about 85% of women of reproductive age experience pre-
menstrual symptoms.1 About 3%–8% of women meet the criteria of more disabling 
and severe symptoms, manifesting as premenstrual syndrome and premenstrual International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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dysphoric disorder, in which emotional (mood-related) 
symptoms   predominate.2 In both premenstrual syndrome 
and premenstrual dysphoric disorder, symptoms abate 
rapidly at the onset of menses or shortly afterwards. 
Because no tests can confirm premenstrual syndrome or 
premenstrual dysphoric disorder, the diagnosis is made on 
the basis of a patient-completed daily symptom calendar 
and the exclusion of other medical disorders.3 Treatment 
is necessary for women with premenstrual syndrome and 
premenstrual dysphoric disorder because of the degree of 
incapacity and distress experienced, which often negatively 
affects quality of life.1,3
Most women with premenstrual syndrome also have to 
cope with abdominal cramping, which is closely associ-
ated with primary dysmenorrhea. Primary dysmenorrhea is 
defined as cramping pain in the lower abdomen occurring 
just before or during menstruation, in the absence of other 
pelvic disease, such as endometriosis. Prevalence rates are 
as high as 90%. Initial presentation of primary dysmenor-
rhea typically occurs in adolescence.4 Women with primary 
dysmenorrhea have higher levels than nondysmenorrhoeic 
women of endometrial prostaglandins F2-α and E2 and leu-
kotrienes, resulting in increased uterine smooth muscle tone 
and stronger, more frequent uterine contractions, as well as 
modification of local blood flow, which taken together are 
responsible for the painful abdominal cramps.4,5
Lifestyle changes, including reducing stress and having 
a balanced healthy diet, including caffeine restriction, are 
often recommended to prevent premenstrual symptoms from 
worsening.1,6 However, to date, pharmacotherapy remains 
the most reliable and effective treatment for abdominal pain 
related to premenstrual syndrome or primary dysmenorrhea. 
Nonsteroidal anti-inflammatory drugs are the mainstay of 
treatment, with the addition of the oral contraceptive pill 
when necessary.4,7
In search of a more natural treatment for premenstrual 
syndrome and dysmenorrhea with a potentially better 
safety profile than a synthetic drug substance, we   developed 
DLBS1442, a proprietary and standardized semipolar 
bioactive extract of the fruit Phaleria macrocarpa. This 
fruit contains tannin, terpenoids, flavonoids, alkaloids, and 
saponins, some of which have been proven preclinically to 
have antioxidant, anti-inflammatory, antiproliferative, and 
anticancer properties.8,9 Fresh P . macrocarpa fruit has a tan-
nin content four times higher than older fruit. As a traditional 
medicine, P . macrocarpa has been used to treat various 
acute illnesses, including rheumatism, due to its analgesic, 
antipyretic, and anti-inflammatory activities. It is often 
also used in combination with other herbs to treat diabetes, 
hypertension, and liver disorders.10
Our previous report indicated that DLBS1442 has an anti-
inflammatory effect, exerted via selective inhibition of cyclo-
oxygenase (COX)-2, an inducible prostaglandin synthase.11 
Abdominal cramping related to premenstrual syndrome result-
ing from uterine vasoconstriction, anoxia, and contractions, 
is mediated by prostaglandins. Therefore, symptomatic relief 
may be obtained from the use of agents that inhibit prosta-
glandin synthesis and have anti-inflammatory properties, so 
hypothetically DLBS1442 could reduce menstruation-related 
abdominal cramp. We conducted the present preliminary 
clinical study to explore this hypothesis, and evaluated the 
anti-inflammatory effect of DLBS1442, indicated by abdomi-
nal pain relief, in women with premenstrual syndrome and/or 
primary dysmenorrhea. Other symptoms commonly observed 
in premenstrual syndrome were also evaluated as secondary 
endpoints. Along with efficacy, the study also evaluated the 
safety of DLBS1442 in human subjects.
Materials and methods
Identification of DLBS1442
DLBS1442 is a dried bioactive extract of P . macrocarpa 
fruit collected in Cikarang, West Java, Indonesia, and has 
been identified by Herbarium Bogoriense, Research Center of 
Biology, Indonesian Institute of Sciences. A quantity of ripe 
P . macrocarpa was powdered using a disk-mill machine, then 
macerated with methanol for 15 minutes, and percolated for 
45 minutes at 50°C. Thereafter, it was evaporated and dried 
using a spray dryer, resulting in DLBS1442, a dry powder 
with a drug to extract ratio of 1:10.
The identification of DLBS1442 was done using thin layer 
chromatography SiO2 gel 60 F254 with chloroform/methanol 
in a ratio of 9:1 as the mobile phase. The eluent was allowed 
to move along the thin layer chromatography plate for a dis-
tance of 8 cm. The chromatogram was then observed under 
ultraviolet light at 254 nm and 366 nm. DLBS1442 was iden-
tified using a high-pressure liquid   chromatography Waters 
(Watertown, MA) 1525 binary pump with a Waters 2487 dual 
λ absorbance as the detector, and a Waters   SunFireTM C18 
(4.6 mm × 250 mm, 5.0 µm) as the column. Absorbance was 
measured at 290 nm. The gradient elution used was methanol 
and acetic acid 0.01% with a flow rate of 1 mL/min, with a 
change in ratio at minutes 3, 15, 17, and 20. Thin layer chro-
matography and high-performance liquid chromatography 
showed various organic compounds, but the major compound, 
having an Rf of 0.6 and a retention time of 10.096 minutes, 
was believed to be benzophenone glycoside.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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clinical study
The clinical study was undertaken between November 2009 
and May 2010, and was conducted in accordance with the 
principles of the Declaration of Helsinki12 and Good Clinical 
Practice.13 Written informed consent was obtained from each 
subject prior to participation in the study, which spanned four 
menstrual cycles. The first and second (control) cycles pro-
filed the baseline severity of premenstrual symptoms, while 
the third and fourth (treatment) cycles evaluated changes in 
severity of premenstrual symptoms after treatment. Two con-
secutive cycles were included in each study period (control 
and treatment) to meet the minimum number of menstrual 
cycles needed to obtain the mean as well as consistency of 
baseline and post-treatment values. Severity of premenstrual 
symptoms was stratified into mild, moderate, and moderate-
to-severe, using a visual analog scale (VAS) evaluation of 
physical and mood symptoms. For each symptom, a subject 
was judged to suffer only mildly from that symptom if the 
mean baseline VAS score was 0–50, moderately if 50–75, 
and moderately-to-severely if .75.
All volunteers met the inclusion criteria, ie: age 18–40 years, 
a regular menstrual cycle (22–35 days per cycle), a history of 
abdominal pain in almost every menstrual cycle since a few 
months or years after menarche (primary dysmenorrhea), and 
at least one affective and one somatic symptom in the 5 days 
before onset of menstruation in two consecutive cycles. The 
affective symptoms included depression, explosive anger, irri-
tability, tension, unhappiness, anxiousness, feelings of isola-
tion, and mood swings; somatic symptoms included abdominal 
pain, breast tenderness, bloating, headache, back pain, and 
swelling of arms and/or legs. Diagnosis of primary dysmen-
orrhea was confirmed by the investigator (a gynecologist), 
using physical examination, abdominal ultrasonography, and 
evaluation of surgical history, as well as a daily subjective 
self-assessment questionnaire.
Subjects were excluded if they were: suffering from 
amenorrhea, secondary dysmenorrhea, or endometriosis; had 
liver, kidney, or other disease, which, in the investigator’s 
opinion, could interfere with trial participation or evaluation 
(eg, anemia, anorexia/bulimia, diabetes mellitus, thyroid 
  disease, mental disease); planning to become pregnant; 
already taking a drug/product regularly to relieve premen-
strual syndrome, especially analgesic drugs (except for rescue 
therapy, ie, paracetamol); on contraception/hormonal or 
antidepressant therapy; substance abusers; or participating in 
any other clinical trial during the course of this study.
No trial medication was given during the control cycles. 
Each eligible subject was given a subject identification number 
and instructed to avoid using other medication, supplements, 
and/or herbal medicines to alleviate premenstrual and men-
strual symptoms during the study period. If the subjects could 
not endure their period pain, they were allowed to use rescue 
pain relief, ie, paracetamol 500 mg, as needed. The number 
of paracetamol tablets used by each subject was recorded. 
In the treatment cycles, DLBS1442 was given as one 100 mg 
capsule either three times daily (for those with moderate-
to-severe baseline abdominal pain) or two times daily (for 
those with mild baseline abdominal pain), for an average of 
six days, ie, the last three days of the luteal phase until the first 
three days of the menstrual phase. Because the study subjects 
had regular menstrual cycles, they were expected to be able 
to predict their next menstrual days, and so were instructed to 
take the investigational product within the scheduled six days. 
The dose of 100 mg was calculated based on the result of our 
preclinical studies of DLBS1442.11 The most effective and 
safe dose providing an anti-inflammatory effect was then 
converted into a daily dose for human subjects.
Throughout the four study cycles, a daily self-assessment 
was made by each subject for the following 20 premenstrual 
symptoms: abdominal pain, breast tenderness, headache, back 
pain, myalgia, nausea, weight gain, overeating,   insomnia, 
fatigue, lack of concentration, irritability, tenseness, unhappy 
feelings, mood swings, anxiousness, depression, anger, 
tearfulness, and social conflict. Subjects recorded scores for 
each item using a VAS, ranging from 0 mm (no symptoms) to 
100 mm (unbearable symptoms), in a symptom diary. VAS is 
a validated tool for rapid and simple assessment of the effect 
size of pain-related symptoms in community practice.14
The primary efficacy endpoint was reduction of VAS 
for abdominal pain from baseline to study end. Secondary 
efficacy endpoints were reductions in VAS from baseline 
to study end for each of the remaining 19 symptoms. The 
data were analyzed descriptively and profiled in a curve 
of VAS versus time point evaluation starting from day 5 
before menstruation (luteal phase) to day 5 of menstruation 
(menstrual phase). The analysis was based on the intention-
to-treat population, which included all women with complete 
baseline values and at least one treatment cycle value, who 
had taken at least one dose of the investigational product.
The safety analysis included all exposed patients who 
had received at least one dose of the investigational product. 
The safety of DLBS1442 was evaluated descriptively for all 
adverse events occurring during the study. Because this was a 
preliminary clinical study, a sample size calculation was not 
required. Nonetheless, we recruited 20–30 healthy subjects 
who had abdominal pain during their menstrual period.International Journal of General Medicine 2011:4
Table 1 Demographic data of study population
Variables (n = 23) Mean (SD)
Age at presentation (years) 27.35 (5.73)
Age of menarche (years) 12.70 (1.46)
Age when PMS first experienced (years) 15.91 (2.78)
Length of menstrual cycle (days) 28.17 (2.96)
Length of menstrual period (days) 3.91 (1.12)
Body weight (kg) 55.56 (9.11)
Abbreviations: sD, standard deviation; PMs, premenstrual syndrome.
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Results
subject characteristics
A total of 27 eligible subjects who had given their written 
informed consent were enrolled in the study. Of these, only 
23 met the criteria for the intention-to-treat efficacy analysis, 
having records for both control cycles and at least one treat-
ment cycle. The other four subjects were not included in the 
analysis because of insufficient data (no available record of a 
treatment cycle). The subject demographics are summarized 
in Table 1. Their age range was 20–40 years. Age at menarche 
was 11–16 years, and symptoms of premenstrual syndrome 
were first experienced at the age of 11–21 years. Menstrual 
cycle length was 21–32 days, with a menstrual bleeding 
duration of 3–7 days.
Efficacy
Primary efficacy endpoint
Abdominal pain was markedly reduced during the treatment 
period compared with the control period (Figure 1). A marked 
reduction was observed at one day before menstruation 
(M-1), and at day 1 (M1) and day 2 of the menstrual period 
(M2), with a VAS reduction of 5.52 ± 11.56 mm (45.50%), 
13.76 ± 28.27 mm (37.46%), and 13.28 ± 29.06 mm 
(44.28%), respectively, from baseline.
The reductions were even more marked when we stratified 
the subjects according to severity of baseline abdominal pain. 
The peak VAS score for abdominal pain was reduced from 
baseline by 8.40 ± 20.19 mm (39.80%), 19.08 ± 19.28 mm 
(53.28%), and 35.70 ± 52.68 mm (54.42%), respectively, for 
the mild, moderate, and moderate-to-severe groups. Most of 
the subjects had mild abdominal pain (n = 13), with some 
having moderate (n = 5) or severe (n = 5) abdominal pain.
Secondary efficacy endpoints
Back pain was also markedly relieved during treatment cycles 
as compared with control cycles (Figure 2). There were much 
lower VAS scores at day 1 and day 3 (M3) of the menstrual 
phase. The reductions from baseline of VAS scores for back 
pain were 9.41 ± 22.89 mm (55.23%), 5.26 ± 19.69 mm 
(44.49%), and 6.52 ± 22.20 mm (64.24%), respectively, 
for M1, M2, and M3. Stratified group analyses showed no 
difference between before and after treatment for the mildly 
symptomatic group (Figure 2A–2D). However, the groups 
with moderate and moderate-to-severe back pain showed 
marked symptom reduction. The baseline back pain score 
in the moderate group peaked at M-1 and decreased by 
26.88 ± 9.24 mm (69.35%) after treatment; in the group 
with moderate-to-severe back pain, a decrease in VAS score 
of 47.20 ± 68.24 mm (56.99%) was recorded at M1. Most 
of the subjects had mild back pain (n = 17), and some had 
moderate (n = 4) or severe (n = 2) back pain.
An obvious reduction in breast tenderness was observed 
in subjects with moderate and moderate-to-severe symptoms 
(Figure 3). In the moderately symptomatic group, the VAS 
peak score for breast tenderness (at M1) decreased from 
31.63 ± 4.25 mm during the control cycle to 17.88 ± 9.42 mm 
in the active treatment cycle, representing a 43.48% reduction 
in breast tenderness as a result of treatment with DLBS1442. 
In the moderate-to-severe symptom group, the peak VAS 
score decreased from 89.00 ± 5.66 mm to 42.69 ± 67.88 mm 
(a 52.03% reduction from baseline).
Overall, the data analysis for myalgia-arthralgia   (Figure 4) 
as well as for headache (Figure 5) demonstrated lower VAS 
scores during the treatment cycle than during the control cycle. 
Stratified analysis based on symptom severity at baseline also 
showed symptomatic relief during the treatment cycle.
The overall VAS score for fatigue during the menstrual 
phase was slightly lower during the treatment cycle than in 
the control cycle. Stratified analysis according to symptom 
severity at baseline also demonstrated better scores during 
the treatment cycle (Figure 6).
There were markedly lower VAS scores for nausea at M1 
during the treatment cycle than for the control cycle. The nausea 
score was reduced from 20.07 ± 25.55 mm to 8.59 ± 20.37 mm, 
representing a reduction of 57.20%. No stratification was done 
for nausea (Figure 7).
DLBS1442 also markedly lowered VAS scores as 
observed in the first two days of the premenstrual phase 
and the first day of the menstrual phase (M-1, M-2, and M1, 
respectively). The peak score for the overeating   symptom 
was reduced at M1 by 64.46% (Figure 8) compared with 
the control cycle. No stratification was done for this 
symptom.
As compared with the control cycle, scores for lack of 
concentration during the treatment cycle were greatly reduced 
on day 1 and day 2 during the menstrual phase (M1 and M2), 
by 64.97% and 45.03%, respectively (Figure 9).International Journal of General Medicine 2011:4
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Figure 1 Mean VAs of abdominal pain from 5 days before (M-5 to M-1) to 5 days during menstruation (M1 to M5): (A) overall, (B) mild, (C) moderate, (D) moderate-to-severe.
Abbreviation: VAs, visual analog scale.
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Figure 2 Mean VAs of back pain from 5 days before (M-5 to M-1) to 5 days during menstruation (M1 to M5): (A) overall, (B) mild, (C) moderate, (D) moderate-to-severe.
Abbreviation: VAs, visual analog scale.
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Figure 3 Mean VAs of breast tenderness from 5 days before (M-5 to M-1) to 5 days during menstruation (M1 to M5): (A) overall, (B) mild, (C) moderate, (D) moderate-to-severe.
Abbreviation: VAs, visual analog scale.
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Figure 4 Mean VAs of myalgia-athralgia from 5 days before (M-5 to M-1) to 5 days during menstruation (M1 to M5): (A) overall, (B) mild, (C) moderate, (D) moderate-to-severe.
Notes: *Marked changes, before versus after.
Abbreviation: VAs, visual analog scale.
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Figure 5 Mean VAs of headache from 5 days before (M-5 to M-1) to 5 days during menstruation (M1 to M5): (A) overall, (B) mild, (C) moderate, (D) moderate-to-severe.
Abbreviation: VAs, visual analog scale.
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Figure 6 Mean VAs of Fatigue from 5 days before (M-5 to M-1) to 5 days during menstruation (M1 to M5): (A) overall, (B) mild, (C) moderate, (D) moderate-to-severe.
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Figure 7 Mean VAs of nausea symptoms from 5 days before (M-5 to M-1) to 5 days 
during menstruation (M1 to M5).
Abbreviation: VAs, visual analog scale.
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Figure 8 Mean VAs of overeating from 5 days before (M-5 to M-1) to 5 days during 
menstruation (M1 to M5).
Abbreviation: VAs, visual analog scale.
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Figure 9 Mean VAs of lack-of-concentration from 5 days before (M-5 to M-1) to 
5 days during menstruation (M1 to M5).
Abbreviation: VAs, visual analog scale.
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Figure 10 Mean VAs of tenseness from 5 days before (M-5 to M-1) to 5 days during 
menstruation (M1 to M5).
Abbreviation: VAs, visual analog scale.
Figure 10 demonstrates improvement in relief of tension 
during the treatment cycle compared with the control cycle. 
The peak score for tension (at M1) during the treatment cycle 
was reduced by 9.78 ± 26.37 mm (85.55%) from baseline 
(control).
Figure 11 shows improvement in relief of unhappy feelings 
during the treatment cycle as compared with the control cycle. 
Significant reduction was observed at M-1, M2, and M3 by 
4.07 ± 14.25 mm (100%), 5.74 ± 24.53 mm (94.97%), and 
4.00 ± 15.52 mm (100%), respectively.
Other symptoms (weight gain, irritability, mood swings, 
anxiousness, depression, anger, tearfulness, and social con-
flict) were slightly improved by treatment with DLBS1442 
(Figure 12). All symptoms, both somatic and affective, abated 
in all subjects during the follicular phase of menstruation, and 
were even absent in some subjects.
Overall, the administration of DLBS1442 for three days 
before and for three days during menstruation relieved 
abdominal pain, other pain-related symptoms, and some 
physiological symptoms experienced by subjects with pre-
menstrual syndrome and/or dysmenorrhea.
safety
Few adverse events were reported, and none were clini-
cally important. Patient reports of adverse events are listed 
in Table 2. The most common events possibly related to 
DLBS1442 were diarrhea and dyspepsia.
Discussion
Abdominal pain experienced by the study subjects during the 
menstrual phase (day 1 and day 2 of menstrual period) in the 
DLBS1442 treatment cycles was much alleviated compared 
with control (baseline) cycles. It is plausible that palliation 
of symptoms was primarily due to the anti-inflammatory 
properties of DLBS1442. Our previous study has shown that 
P . macrocarpa downregulates the phosphoinositide 3-kinase/
AKT pathway which further downregulates the eicosanoid 
pathway.9,15 VAS reductions for abdominal pain on day 1 
and day 2 of the menstrual period were 13.76 ± 28.27 mm 
(37.46%) and 13.28 ± 29.06 mm (44.28%), respectively. Such 
a magnitude of reduction has significant practical importance. 
Regardless of baseline pain severity, the difference in VAS 
pain score (on a 100 mm scale) should be 9–14 mm at a International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 11 Mean VAs of unhappy feeling 5 days before (M-5 to M-1) to 5 days during 
menstruation (M1 to M5).
Abbreviation: VAs, visual analog scale.
minimum to be considered clinically significant.16–18 It has 
also been reported that the minimal clinically significant 
difference in VAS pain score does not differ with gender, 
age, or cause of pain.17
Subgroup analysis in the mild, moderate, and moderate-
to-severe groups (each with peak VAS abdominal pain 
scores of ,25 mm, 25–50 mm, and .50 mm, respectively) 
demonstrated that in cycles during which the subjects were 
treated with DLBS1442, the peak scores were much lower 
than those of baseline cycles. The reductions in peak score 
for the subgroups with mild, moderate, and severe abdominal 
pain were 8.40 ± 20.19 mm (39.80% lower from baseline), 
19.08 ± 19.28 mm (53.28%), and 35.70 ± 52.68 mm (54.42%), 
respectively. Given the minimal clinically significant differ-
ence in VAS pain score being 9–14 mm, the reductions in 
the moderately severe and severe groups were clinically 
significant, but not so in the mild group. This is not surpris-
ing, because the more severe the baseline pain, the greater 
the magnitude of pain reduction.
Abdominal pain in premenstrual syndrome and primary 
dysmenorrhea is caused by increased tone and contrac-
tions in the musculature of the uterus, which is brought 
about by increased release of endometrial prostaglandins.4 
  Nonsteroidal anti-inflammatory drugs have long been used 
as the treatment of choice for primary dysmenorrhea due to 
their mode of action as prostaglandin synthesis inhibitors. 
The most studied nonsteroidal anti-inflammatory drugs in 
women with premenstrual syndrome are mefenamic acid and 
naproxen sodium.19 DLBS1442 similarly inhibits the transfor-
mation of arachidonic acid into prostaglandins by suppressing 
COX-2 activity,11 and hence may also alleviate pain related 
to premenstrual syndrome, especially abdominal pain, as 
demonstrated in our study. In addition, DLBS1442 seemed 
to relieve the mastalgia accompanying breast tenderness 
(Figure 3), a feature that nonsteroidal anti-inflammatory 
drugs do not appear to have, even though they may alleviate 
a wide range of symptoms of premenstrual syndrome.7
In addition to palliation of abdominal pain, other pains 
related to premenstrual syndrome were also relieved by 
DLBS1442, including back pain (9.41 ± 22.89 mm [55.23%] 
reduction in peak score) and fatigue (9.65 ± 26.72 mm 
[53.30%] reduction in peak score). While headache and 
myalgia/arthralgia were also consistently alleviated, the 
reductions were not of clinical importance because they were 
less than 9 mm. Such a slight reduction was again dependent 
on the baseline severity of symptoms, which in our study 
was only mild (13.04 ± 23.44 mm and 17.63 ± 22.62 mm 
for headache and myalgia/arthralgia, respectively). However, 
subgroup analyses for the mild, moderate, and moderate-to-
severe groups demonstrated that the peak score reduction 
for each of the pain-related symptoms (back pain, fatigue, 
headache, and myalgia/arthralgia) was greater and more of 
clinical importance in the moderate and moderate-to-severe 
pain groups (14–83 mm VAS reduction from baseline) than 
in the mild group (,4 mm VAS reduction from baseline).
Abdominal pain, back pain, myalgia/arthralgia, headache, 
and fatigue are all symptoms related to pain and inflammation 
that can be reduced by prostaglandin suppression.   Alleviation 
of these symptoms also indicates the anti-inflammatory 
  activity of DLBS1442. In addition, there is emerging evi-
dence suggesting that hormonal therapies may help to relieve 
menstrual-related migraine.20 Our previous in vitro study of 
DLBS1442 demonstrated its effect on the estrogen receptor,21 
which is likely to account for the activity of the extract in 
relieving headache related to premenstrual syndrome.
Premenstrual nausea that usually accompanies abdomi-
nal cramping was also ameliorated by DLBS1442. The 
nausea VAS score peaking at menstrual day 1 was reduced 
by 11.48 ± 23.80 mm from baseline (20.07 ± 25.55 mm). 
  However, such a reduction was not clinically significant 
because the minimal clinically significant difference in 
nausea should be 15 mm on a VAS.22
Breast tenderness is usually associated with an imbalance 
in female hormones, ie, estrogen, progesterone, and prolactin. 
Monthly changes in levels of those hormones may cause fluid 
retention in the breast, experienced as a sensation of breast 
fullness and pain.6 DLBS1442 ameliorated this symptom, 
and particularly so in a subgroup of moderately severe cases. 
In the latter group, DLBS1442 reduced the peak VAS score 
by up to 44 mm from baseline. Consistent with this find-
ing, other symptoms which were also associated with this 
  hormonal imbalance, including overeating, unhappy feelings, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 12 Mean VAs of weight gain (A), irritability (B), mood swings (C), anxiousness (D), depression (E), anger (F), tearfulness (G), and social conflict (H), from 5 days 
before (M-5 to M-1) to 5 days during menstruation (M1 to M5).
Abbreviation: VAs, visual analog scale.
and tension, were also relieved by DLBS1442. However, 
because these symptoms were only very mild at baseline, 
the reduction was not of significance. Although these results 
have yet to be confirmed by more thorough preclinical and 
  clinical studies, they may serve an early indication of the 
effect of DLBS1442 on hormonal imbalance and on the 
estrogen receptor, and are consistent with the results of a 
previous in vitro study of this extract.21
Other symptoms, like weight gain, insomnia, irritability, 
unhappy feelings, mood swings, anxiousness, depression, 
anger, tearfulness, and social conflict, were also ameliorated 
by DLBS1442 but not to a significant extent. The low VAS International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 2 reported adverse events
Description AE (n) Respondents with AE (n) % AE numbers
Based on total respondents with AE Based on total number of AEs
constipation 1 1 12.5 3.7
Diarrhea 6 4 75.0 22.2
Pharyngitis 2 2 25.0 7.4
Fever 2 2 25.0 7.4
Arthritis 1 1 12.5 3.7
Dizziness 2 2 25.0 7.4
Dyspepsia 4 3 50.0 14.8
Influenza 3 3 37.5 11.1
common cold 1 1 12.5 3.7
cough 2 2 25.0 7.4
Typhoid 2 2 25.0 7.4
Mild urticaria 1 1 12.5 3.7
Total events = 27 Total respondents = 8
Abbreviation: Ae, adverse event.
scores for these symptoms at baseline (control cycles) are 
likely to account for the only slight difference between control 
and treatment cycles.
The safety profile of DLBS1442 was investigated based 
on adverse event reporting. Overall, there were few adverse 
events reported and most were mild in severity. There were 
four reports of dyspepsia after taking DLBS1442. These 
events were possibly related to the mechanism of action of 
DLBS1442, ie, inhibition of COX. DLBS1442 is selective for 
COX-2, yet slightly affects COX-1, as reported by a previous 
preclinical study.11 Thus, adverse events related to peptic 
ulcer should be addressed specifically in a larger trial.
We realize that our study was preliminary and needs a 
larger randomized controlled trial for the results to be con-
firmed. However, the consistency of improvement found in 
most of the observed symptoms may be regarded as a promis-
ing indication of the benefits of DLBS1442 in treating women 
with premenstrual syndrome and/or primary dysmenorrhea.
Conclusion
This preliminary study indicates that DLBS1442 is effective 
in alleviating primary dysmenorrhea as well as abdominal 
pain and other symptoms related to premenstrual syndrome. 
The extract was also safe and well tolerated in female subjects 
with premenstrual syndrome and/or dysmenorrhea.
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